SCHEMBL7228178

SCHEMBL7228178

CCOC(=O)COc1ccc(CBr)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.62
NPSR1 Q6W5P4 1/20 0.62
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
HPGD P15428 2/20 0.51
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.51
MAPT P10636 1/20 0.51
PTPN1 P18031 1/20 0.51
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.49
TBXAS1 P24557 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ADRB2 P07550 2/20 0.48
ADRB1 P08588 2/20 0.48
ADRB3 P13945 2/20 0.48
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7723659 0.87 GAA (0.59) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL5202817 0.86 GAA (0.66) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL8321862 0.85 GAA (0.64) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL11815554 0.84 GAA (0.72) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL1668484 0.83 GAA (0.62) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL7918868 0.83 GAA (0.62) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL419376 0.83 GAA (0.66) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL1482201 0.83 PTGS2 (0.54) GAAALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL30257467 0.83 LTA4H (0.56) MAPTSMN1; SMN2
SCHEMBL1107148 0.82 GAA (0.70) GAANPSR1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534496-B1 Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2003-03-18 US disclosed
US-6310217-B1 ANTIINFLAMMATORY AND ANALGESIC AGENTS MERCKLE GMBH (DE) 2001-10-30 US disclosed
EP-0975624-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS Takeda Chemical Industries, Ltd. (JP) 2000-02-02 EP disclosed
EP-0912175-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-09-08 EP disclosed
EP-0912175-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1999-05-06 EP disclosed
US-5854245-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-12-29 US disclosed
WO-1998046590-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-22 WO disclosed
WO-1998000134-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-01-08 WO disclosed
US-5374641-A Thromboxane synthetase inhibitors, prostaglandin H2 antagonist , anticoagulants and antiallergens TERUMO KABUSHIKI KAISHA (JP) 1994-12-20 US disclosed
EP-0501876-A1 N-(3-pyridylalkyl)sulfonamide derivative and pharmaceutical preparation containing thereof TERUMO KABUSHIKI KAISHA (JP) 1992-09-02 EP disclosed
EP-0083228-B1 PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES ICI AMERICAS INC. (US) 1985-05-15 EP disclosed
US-4499299-A Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1985-02-12 US disclosed
US-4461905-A THROMBOXANE SYNTHETASE INHIBITOR INTERMEDIATE ONO PHARMACEUTICAL CO., LTD. (JP) 1984-07-24 US disclosed
EP-0083228-A1 Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1983-07-06 EP disclosed